Mark Leo Michaels

This inventor holds 28 USPTO granted patents and 22 published patent applications, plus 3 CIPO patents and 12 EPO patents, primarily in Biopharmaceutical Innovations. Top assignees: Amgen Inc., Atara Biotherapeutics, Inc., Other. Active years: 2000-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Leo Michaels. Retrieved from https://idiyas.com/inventor/mark-leo-michaels

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 12 (Patent Applications = 23)

Average Co-Inventor Count = 5.9

ph-index = 12

Forward Citations = 531(Granted Patents)

Location History:

Encinco, CA (US) (2016)
Encino, CA (US) (2000 - 2023)

Company Filing History:

Atara Biotherapeutics, Inc.

patents

1 out of 834,513

Other

patents

Years Active: 2000-2026

Loading Chart...

Areas of Expertise:

FGF21 Mutants

Receptor Polypeptides

Bispecific Antibodies

Metabolic Disorders

Diabetes Treatments

Stabilized Proteins

Nucleic Acids

Fluorescent Proteins

Heterodimeric Molecules

Polypeptide Variants

Gastric Inhibitory Peptide

Non-Alcoholic Steatohepatitis

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729229 - ENGINEERED NRG-1 VARIANTS WITH IMPROVED SELECTIVITY TOWARD ErbB4 BUT NOT AGAINST ErbB3 (2026-09-08),

2. 12630608 - STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF (2026-05-19),

3. 12435149 - Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists (2025-10-07),

4. 11840558 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2023-12-12),

5. 11753475 - Bispecific-Fc molecules (2023-09-12),

6. 11685770 - Stabilized receptor polypeptides and uses thereof (2023-06-27),

7. 11634502 - Heterodimeric bispecific antibodies (2023-04-25),

8. 11072640 - Methods of treating non-alcoholic steatohepatitis using FGF21 mutants (2021-07-27),

9. 10308704 - Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof (2019-06-04),

10. 10189890 - Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods (2019-01-29),

11. 10011642 - Methods of treating of diabetes and obesity using FGF21 mutants (2018-07-03),

12. 9708375 - Inhibitory polypeptides specific to WNT inhibitors (2017-07-18),

13. 9688756 - Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor (2017-06-27),

14. 9517264 - Human FGF receptor and β-Klotho binding proteins (2016-12-13),

15. 9493530 - FGF21 mutants comprising a mutation at position 98, 171 and/or 180 (2016-11-15),

Title: Mark Leo Michaels: Innovator in Medical Biotechnology

Introduction

Mark Leo Michaels is a distinguished inventor based in Encino, California, known for his significant contributions to the field of medical biotechnology. With an impressive portfolio of 25 patents, he has made remarkable strides in developing innovative treatments for various metabolic disorders.

Latest Patents

Michaels' most recent inventions include groundbreaking technologies aimed at treating non-alcoholic steatohepatitis and novel bispecific Fc molecules. His patent titled "Methods of treating non-alcoholic steatohepatitis using FGF21 mutants" details the invention of nucleic acid molecules encoding FGF21 mutant polypeptides, as well as pharmaceutical compositions that utilize these polypeptides. This development holds promise for effectively addressing metabolic disorders. Additionally, his invention of "Bispecific-Fc molecules" describes a novel bispecific molecule containing an Fc polypeptide chain alongside immunoglobulin variable regions, along with associated pharmaceutical formulations and methods of use.

Career Highlights

Throughout his career, Mark Leo Michaels has worked with prominent biotechnology companies such as Amgen Inc. and Atara Biotherapeutics, Inc. His expertise and innovative mindset have played a crucial role in advancing medical research and developing effective treatment options.

Collaborations

Michaels has collaborated with esteemed colleagues, including Jeonghoon Sun and Yue-Sheng Li. These partnerships have fostered a collaborative environment that encourages innovation and the exchange of ideas, further propelling advancements in the field.

Conclusion

Mark Leo Michaels embodies the spirit of innovation in the biotechnological landscape. His continuous efforts and intellectual contributions not only enhance understanding in medical science but also pave the way for future breakthroughs in treatment methodologies. His work underscores the crucial intersection of scientific inquiry and practical application, inspiring the next generation of inventors in the industry.

Profile summary based on public USPTO records.